Gianluca Gaïdano

Active 1989–2026

Also published as
Gianluca Gaidano
258
Papers
35,778
Citations
111
h-index
249
i10-index

Citations

Citations per year for Gianluca Gaïdano1990: 2 citations1991: 9 citations1992: 27 citations1993: 55 citations1994: 44 citations1995: 67 citations1996: 56 citations1997: 53 citations1998: 88 citations1999: 122 citations2000: 112 citations2001: 104 citations2002: 127 citations2003: 126 citations2004: 70 citations2005: 97 citations2006: 71 citations2007: 104 citations2008: 78 citations2009: 95 citations2010: 101 citations2011: 166 citations2012: 255 citations2013: 286 citations2014: 286 citations2015: 276 citations2016: 345 citations2017: 338 citations2018: 313 citations2019: 1,069 citations2020: 1,247 citations2021: 1,279 citations2022: 1,036 citations2023: 735 citations2024: 1,078 citations2025: 499 citations2026: 15 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,500 citing papers, 24% of this breakdownItaly: 1,345 citing papers, 9.2% of this breakdownUnited Kingdom: 1,023 citing papers, 7% of this breakdownGermany: 1,000 citing papers, 6.9% of this breakdownFrance: 811 citing papers, 5.6% of this breakdownChina: 745 citing papers, 5.1% of this breakdownSpain: 674 citing papers, 4.6% of this breakdownCanada: 473 citing papers, 3.3% of this breakdownSwitzerland: 467 citing papers, 3.2% of this breakdownNetherlands: 374 citing papers, 2.6% of this breakdownAustralia: 371 citing papers, 2.5% of this breakdownJapan: 288 citing papers, 2% of this breakdown
0%24%Other 24%

Fields

  • Medicine76.6%
  • Biochemistry, Genetics and Molecular Biology18.1%
  • Immunology and Microbiology3.9%
  • Neuroscience0.3%
  • Computer Science0.2%
  • Economics, Econometrics and Finance0.1%
  • Other0.8%

Topics

  • Lymphoma Diagnosis and Treatment12.3%
  • Chronic Lymphocytic Leukemia Research8.9%
  • Viral-associated cancers and disorders4%
  • CAR-T cell therapy research3.3%
  • Acute Myeloid Leukemia Research2.7%
  • Multiple Myeloma Research and Treatments2.6%
  • Other66.2%

Coauthors

All papers

Open in search
  1. Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Nature Biotechnology 2021 cited by 366

  2. Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Fong Clow, Lori Styles, Danelle F. James, Thomas J. Kipps - New England Journal of Medicine 2015 cited by 1,562

  3. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study

    Authors: , , , , , , , , , , , , , , , , - The Lancet Oncology 2020 cited by 519

  4. Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2018 cited by 496

  5. Dynamic Risk Profiling Using Serial Tumor Biomarkers for Personalized Outcome Prediction

    Authors: , , , , , , , , , , , , , , , , , , , , , , - Cell 2019 cited by 239

  6. Effect of Recombinant Zoster Vaccine on Incidence of Herpes Zoster After Autologous Stem Cell Transplantation

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , for the ZOE-HSCT Study Group Collaborators - JAMA 2019 cited by 257

  7. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Norbert Blesing, Terrance Comeau, Teresa del Campo, Patricia Disperati, Richard Eek, Hyeon‐Seok Eom, Gianluca Gaïdano, Sebastian Grosicki, Thierry Guillaume, Wojciech Homenda, William Ying Khee Hwang, Nikolay Ilyin, Anna Johnston, Seok Jin Kim, Ching-Yuan Kuo, А Ю Кувшинов, Dong‐Gun Lee, Jae Hoon Lee, Je‐Jung Lee, Stéphane Leprêtre, Albert Kwok-Wai Lie, Alessandro Lucchesi, Ahmed Ijaz Masood, Naheed Mir, Anna Carolina Miranda Castillo, Kathleen M. Mullane, Alexandr Myasnikov, Raquel Oña Navarrete, Karlis Pauksens, Andrew Peniket, Jaime Pérez de Oteyza, David Pohlreich, Humphrey Pullon, Philippe Quittet, Philippe Rodon, Lars Rombo, Olga Samoylova, Johan Berglund, Ariah Schattner, Dominik Selleslag, Marjatta Sinisalo, Faisal Sultan, Koen Theunissen, Paul Turner, Po-Nan Wang, Lucrecia Yáñez San Segundo, Jo‐Anne H. Young, Pierre Zachée, Francesco Zaja - The Lancet Infectious Diseases 2019 cited by 254

  8. Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Franco Cavalli, Emanuele Zucca, Luigi Maria Larocca, Gianluca Gaïdano, Stefan Hohaus, Carmelo Carlo‐Stella, Davide Rossi - Blood 2018 cited by 338

  9. Detection of early seeding of Richter transformation in chronic lymphocytic leukemia

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Francesc Bosch, Marta Aymerich, Anna Enjuanes, Sílvia Ruiz-Gaspà, Armando López‐Guillermo, Pedro Jares, Sı́lvia Beà, Salvador Capella-Gutiérrez, Josep Lluis Gelpí, Núria López-Bigas, David Torrents, Peter J. Campbell, Marta Gut, Davide Rossi, Gianluca Gaïdano, Xosé S. Puente, Pablo M. García-Rovés, Dolors Colomer, Holger Heyn, Francesco Maura, José I. Martín‐Subero, Elı́as Campo - Nature Medicine 2022 cited by 135

  10. Inactivating mutations of acetyltransferase genes in B-cell lymphoma

    Authors: , , , , , , , , , , , , , , , , , - Nature 2011 cited by 942

  11. Genetics of Follicular Lymphoma Transformation

    Authors: , , , , , , , , , , , , , , , , , , - Cell Reports 2014 cited by 585

  12. BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Renata Walewska, Anders Österborg, Diego Cortese, Pamela Ranghetti, Panagiotis Baliakas, Κώστας Σταματόπουλος, Lydia Scarfò, Richard W. Rosenquist, Paolo Ghia - Blood Advances 2023 cited by 66

  13. Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2016 cited by 348

  14. Genetic mechanisms of HLA-I loss and immune escape in diffuse large B cell lymphoma

    Authors: , , , , , , , , , , , , , , , , , , , - National Academy of Sciences, Proceedings of the National Academy of Sciences 2021 cited by 93

  15. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Wee Joo Chng - The Lancet Oncology 2015 cited by 849

  16. The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - Blood 2011 cited by 377

  17. Diffuse large B-cell lymphoma genotyping on the liquid biopsy

    Authors: , , , , , , , , , , , , , , - Blood 2017 cited by 258

  18. Analysis of the coding genome of diffuse large B-cell lymphoma

    Authors: , , , , , , , , , , , , , , , , - Nature Genetics 2011 cited by 963

  19. Short Diagnosis-to-Treatment Interval Is Associated With Higher Circulating Tumor DNA Levels in Diffuse Large B-Cell Lymphoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2021 cited by 78

  20. Convergent Mutations and Kinase Fusions Lead to Oncogenic STAT3 Activation in Anaplastic Large Cell Lymphoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Gianluca Gaïdano, Stefano Pileri, Enrico Tiacci, Brunangelo Falini, Leonard D. Shultz, Laurence Mévellec, Jorge Vialard, Roberto Piva, Francesco Bertoni, Raúl Rabadán, Giorgio Inghirami - Cancer Cell 2015 cited by 442

  21. Infections by carbapenem-resistant Klebsiella pneumoniae in SCT recipients: a nationwide retrospective survey from Italy

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Attilio Rovelli, Clara Pecoraro, Alessandro Busca, Francesca Carraro, Franca Fagioli, Susanna Gallo, Daniele Caravelli, Marco De Gobbi, Giuseppe Saglio, Claudia Castellino, Nicola Mordini, Gianluca Gaïdano, Luca Nassi, R Raimondi, Michele Vespignani, Anna Maria Scattolin, Irene Sara Panizzolo, Simone Cesaro, Anna Candoni, Francesca Patriarca, Andrea Bacigalupo, Anna Maria Raiola, Elio Castagnola, Edoardo Lanino, Marta Stanzani, Giuseppe Bandini, Erika Massaccesi, Arcangelo Prete, Simona Bassi, Daniele Vallisa, Cecilia Caramatti, Franco Aversa, Eliana Zuffa, Stefano Guidi, Alberto Bosi, Veronica Tintori, Anna Paola Iori, Saveria Capria, Laura Cudillo, William Arcese, Teresa Dentamaro, Paolo de Fabritiis, Barbara Anaclerico, Anna Chierichini, Monica Piedimonte, Antonella Ferrari, Francesco Marchesi, Andrea Mengarelli, Elisabetta Cerchiara, Maria Cristina Tirindelli, Javid Gaziev, Alessandro Severino, Ignazio Majolino, Patrizia Chiusolo, Simona Sica, Alice Bertaina, Barbarella Lucarelli, Maria Speranza Massei, Alessandra Carotti, Katia Perruccio, Maurizio Caniglia, Stella Santarone, Paolo Di Bartolomeo, Serena Mazzotta, Piero Galieni, Attilio Olivieri, Gennaro De Rosa, Antonio M. Risitano, Mario Delia, Giorgina Specchia and 12 more - Bone Marrow Transplantation 2014 cited by 188

  22. Results from a phase I/II trial of cusatuzumab combined with azacitidine in patients with newly diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapy

    Authors: , , , , , , , , , , , , , , , , , , , - Haematologica 2023 cited by 35

  23. Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - Blood 2014 cited by 372

  24. Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma

    Authors: , , , , , , , , , , , , , , , , , , , , - Haematologica 2021 cited by 140